SUPPLEMENTAL WORK-SARS-COV-2

补充工作-SARS-COV-2

• 批准号: 10397497
• 负责人: MICHAEL KAYTOR
• 金额: $ 187.27万
• 依托单位: HUMANETICS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10397497
• 关键词: 2019-nCoV; Antioxidants; COVID-19; COVID-19 patient; Cancer Patient; Chest; Clinic; Diagnostic radiologic examination; Genistein; Hospitals; Impairment; Injury; Malignant neoplasm of lung; Mediating; Medical center; Oral; Pulmonary Fibrosis; Pulmonary Inflammation; Quality of life; Radiation; Radiation therapy; Work; efficacy testing; lung injury; nanoformulation; phase II trial; pulmonary function

The company will initiate a phase 2 trial to evaluate BIO 300 (oral, genistein antioxidant) to mitigate impaired pulmonary function in COVID-19 patients recently discharged from the hospital. COVID-19- and radiation-mediated lung damage share overlapping mechanisms of injury, and Humanetics already has BIO300 under study in the clinic to treat pneumonitis and pulmonary fibrosis in lung cancer patients receiving thoracic radiotherapy.

该公司将启动一项2期试验，以评估BIO 300（口服，染料木黄酮抗氧化剂），以减轻最近出院的COVID-19患者的肺功能受损。COVID-19和辐射介导的肺损伤具有重叠的损伤机制，Humanetics已经在临床研究BIO 300，用于治疗接受胸部放疗的肺癌患者的肺炎和肺纤维化。